| 產品編號 | bs-9454R-PE-Cy5 |
| 英文名稱 | Rabbit Anti-SLC27A6/PE-Cy5 Conjugated antibody |
| 中文名稱 | PE-Cy5標記的脂肪酸轉運蛋白6抗體 |
| 別 名 | very long-chain 2; ACSVL2; FACVL2; FATP 6; FATP-6; FATP6; Fatty acid coenzyme A ligase, very long chain 2; Fatty acid transport protein 6; Fatty-acid-coenzyme A ligase; hVLCS H1; hVLCS-H1; Long-chain fatty acid transport protein 6; S27A6_HUMAN; SLC27A6; solute carrier family 27 fatty acid transporter member 6; Solute carrier family 27 member 6; Very long chain acyl CoA synthetase homolog 1; Very long-chain acyl-CoA synthetase homolog 1; VLCS H1; VLCSH1. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 心血管 免疫學 信號轉導 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Dog, Horse, Rabbit, Zebrafish, Fruit Fly, (Drosophilamelanogaster),) |
| 產品應用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 70kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human SLC27A6/ACSVL2 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: Acyl-coenzyme A synthetases (ACSs) are a large family of related enzymes known to catalyze the fundamental initial reaction in fatty acid metabolism. The ACS family is roughly characterized based on fatty acid chain length preference amongst different members. The nomenclature in the ACS family reflects this relationship and includes short-chain ACS (ACSS), medium-chain ACS (ACSM), long-chain ACS (ACSL) and very long-chain ACS (ACSVL). ACSVL family members are capable of activating both long (LCFAs) and very long-chain fatty acids (VLCFAs). There are six members of the human ACSVL subfamily, which have been described as solute carrier family 27A (SLC27A) gene products. They represent a group of evolutionarily conserved fatty acid transport proteins (FATPs) recognized for their role in facilitating translocation of long-chain fatty acids across the plasma membrane. The family nomenclature has recently been unified with their respective acyl-CoA synthetase family designations: ACSVL1 (FATP2), ACSVL2 (FATP6), ACSVL3 (FATP3), ACSVL4 (FATP1), ACSVL5 (FATP4) and ACSVL6 (FATP5). ACSVLs have unique expression patterns and are found in major organs of fatty acid metabolism, such as adipose tissue, liver, heart and kidney. ACSVL2 is a 619 amino acid multi-pass membrane protein. Encoded by a gene that maps to human chromosome 5q23.3, ACSVL2 may function as the predominant fatty acid protein transporter in heart. Function: Involved in translocation of long-chain fatty acids (LFCA) across the plasma membrane. Thought to function as the predominant fatty acid protein transporter in heart. Subcellular Location: Membrane. Cell membrane; sarcolemma. In heart is exclusively located on the sarcolemma in areas juxtaposed with small blood vessels where it colocalizes CD36. Tissue Specificity: Strongly expressed in heart and localizes to cardiac myocytes. Expressed at moderate levels in placenta, testis, and adrenal glands. Expressed at very low levels in kidney, bladder and uterus. Similarity: Belongs to the ATP-dependent AMP-binding enzyme family. Database links: Entrez Gene: 28965 Human Entrez Gene: 225579 Mouse Omim: 604196 Human SwissProt: Q9Y2P4 Human Unigene: 49765 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
